Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Products under Development by Stage of Development | 9 | 1 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Products under Development by Therapy Area | 10 | 1 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Products under Development by Indication | 11 | 2 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Products under Development by Companies | 15 | 3 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Products under Development by Universities/Institutes | 18 | 2 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Therapeutics Assessment | 20 | 6 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 1 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Companies Involved in Therapeutics Development | 26 | 14 |
| AbbVie Inc | 26 | 1 |
| Affibody AB | 27 | 1 |
| Anacor Pharmaceuticals, Inc. | 28 | 1 |
| Apexigen, Inc. | 29 | 1 |
| Cell Medica Limited | 30 | 1 |
| Handok Inc. | 31 | 1 |
| Immune Response BioPharma, Inc. | 32 | 1 |
| Novartis AG | 33 | 1 |
| Omnitura Therapeutics Inc. | 34 | 1 |
| Opsona Therapeutics Limited | 35 | 1 |
| Peptinov SAS | 36 | 1 |
| R-Pharm | 37 | 1 |
| Regeneron Pharmaceuticals Inc | 38 | 1 |
| TWi Pharmaceuticals, Inc. | 39 | 1 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Drug Profiles | 40 | 27 |
| ABT-981 Drug Profile | 40 | 1 |
| AN-4161 Drug Profile | 41 | 1 |
| APX-002 Drug Profile | 42 | 1 |
| canakinumab Drug Profile | 43 | 5 |
| diacerein Drug Profile | 48 | 3 |
| DLX-2323 Drug Profile | 51 | 1 |
| DLX-2681 Drug Profile | 52 | 1 |
| HL-2351 Drug Profile | 53 | 1 |
| IR-1000 Drug Profile | 54 | 1 |
| IR-1002 Drug Profile | 55 | 1 |
| IR-888 Drug Profile | 56 | 1 |
| melittin Drug Profile | 57 | 1 |
| OMN-54 Drug Profile | 58 | 2 |
| PPV-01 Drug Profile | 60 | 1 |
| Recombinant Protein to Inhibit IL-1 Beta for Autoimmune Disorder and Inflammation Drug Profile | 61 | 1 |
| rilonacept Drug Profile | 62 | 3 |
| RPH-104 Drug Profile | 65 | 1 |
| Small Molecule Inflammasome Modulator Programme Drug Profile | 66 | 1 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Dormant Projects | 67 | 5 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Discontinued Products | 72 | 3 |
| Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Featured News &Press Releases | 75 | 9 |
| Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment | 75 | 1 |
| Jun 23, 2016: CHMP adopts extension to existing therapeutic indication for Canakinumab | 75 | 1 |
| Apr 27, 2016: Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes | 76 | 1 |
| Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir | 76 | 1 |
| Mar 23, 2016: Turkish signature on the biomolecules study Hurriyet | 77 | 1 |
| Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients | 78 | 1 |
| Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting | 79 | 1 |
| Oct 27, 2015: TWi Biotechnology Receives Notice of Patent Allowance in Korea for its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes | 79 | 1 |
| Aug 03, 2015: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia | 80 | 1 |
| Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan | 80 | 1 |
| Dec 22, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China | 81 | 1 |
| Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan | 81 | 1 |
| Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States | 81 | 1 |
| Jun 26, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States | 82 | 1 |
| Sep 10, 2013: TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States | 82 | 2 |
| Appendix | 84 | 2 |
| Methodology | 84 | 1 |
| Coverage | 84 | 1 |
| Secondary Research | 84 | 1 |
| Primary Research | 84 | 1 |
| Expert Panel Validation | 84 | 1 |
| Contact Us | 84 | 1 |
| Disclaimer | 85 | 1 |